ArticleJournal of experimental & clinical cancer research : CR2014
Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model.
Article in Journal of experimental & clinical cancer research : CR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Depression remodels tumor microenvironment to drive tumor progression: Bio-behavioural signalling pathways and clinical interventions.Journal of advanced research · 2026Review
- The neural niche in cancer: mechanistic insights into tumor-neuron-immune crosstalk and therapeutic opportunities.Frontiers in cell and developmental biology · 2026Review
- Stress Biology in Cancer: Neuroendocrine-Immune Mechanisms Linking Tumor Progression to Translational Interventions.Cancer communications (London, England) · 2026Review
- Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer.International journal of molecular sciences · 2025Review
- Role of transforming growth factor-β1 pathway in angiogenesis induced by chronic stress in colorectal cancer.Cancer biology & therapy · 2024Article
- The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response.Frontiers in oncology · 2024Review
- The neural addiction of cancer.Nature reviews. Cancer · 2023Review
- Chronic stress in solid tumor development: from mechanisms to interventions.Journal of biomedical science · 2023Review
- Psychological distress and eustress in cancer and cancer treatment: Advances and perspectives.Science advances · 2022Review
- Stress and cancer: mechanisms, significance and future directions.Nature reviews. Cancer · 2021Review
- Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.Targeted oncology · 2021Article
- Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer.International journal of molecular sciences · 2021Review
- Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments.Frontiers in cell and developmental biology · 2021Review
- Topical 2'-Hydroxyflavanone for Cutaneous Melanoma.Cancers · 2019Article
- β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of βBritish journal of pharmacology · 2019Review
- Sympathetic stimulation with norepinephrine may come at a cost.Neural regeneration research · 2019Article
- Role of the Nervous System in Tumor Angiogenesis.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2018Review
- Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma.Oncotarget · 2018Article
- Effects of trauma, hemorrhagic shock, and chronic stress on lung vascular endothelial growth factor.The Journal of surgical research · 2017Article
- The role of stress and beta-adrenergic system in melanoma: current knowledge and possible therapeutic options.Journal of cancer research and clinical oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSunitinib alone exhibits satisfactory efficacy in several mouse homografts and xenografts but unsatisfactory efficacy in many kinds of solid tumors in clinic. Different from animals, receiving a diagnosis of cancer impacts chronic stress on patients. Here, we examine whether norepinephrine (NE), one of the most potent stress related hormones, leads to the difference in the efficacy of sunitinib between clinical and preclinical trials.
methodsThe influence of NE on mouse melanoma B16F1 cells under sunitinib was evaluated in vitro and in vivo. The β-AR/cAMP/PKA (β-adrenoceptor/cyclic adenosine monophosphate/protein kinase A) signaling pathway was also evaluated in human lung adenocarcinoma cells.
resultsWe found that NE upregulated the expression of VEGF, IL-8 and IL-6 in vitro and stimulated tumor growth in vivo, which was mediated by β-AR/cAMP/PKA signaling pathway and could be inhibited by propranolol, a β-blocker for hypertension for decades.
conclusionsThis research indicates exogenous norepinephrine attenuates the efficacy of sunitinib, and a combination of sunitinib and propranolol might be suggested as a new strategy in solid tumor in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.